Clinical Trials Logo

Filter by:
NCT ID: NCT03847090 Terminated - Clinical trials for Enteric Hyperoxaluria

Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria

URIROX-2
Start date: August 26, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy, durability and long-term safety of reloxaliase in patients with enteric hyperoxaluria.

NCT ID: NCT03844932 Terminated - Colitis, Ulcerative Clinical Trials

A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

Start date: January 24, 2019
Phase: Phase 2
Study type: Interventional

Study CYC-202 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of ST-0529 in subjects with moderately to severely active UC, defined as a score of 5 to 9 on the 3-Component Adapted Mayo Score (comprised of rectal bleeding, stool frequency and endoscopy sub-scores; score range 0-9).

NCT ID: NCT03843125 Terminated - Clinical trials for Systemic Lupus Erythematosus

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

SLE-BRAVE-X
Start date: September 9, 2019
Phase: Phase 3
Study type: Interventional

The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).

NCT ID: NCT03836716 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

Start date: September 19, 2019
Phase: Phase 3
Study type: Interventional

A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS) who have completed the ORARIALS-01 trial.

NCT ID: NCT03831191 Terminated - Atopic Dermatitis Clinical Trials

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

ADmIRe
Start date: February 12, 2019
Phase: Phase 2
Study type: Interventional

The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).

NCT ID: NCT03829657 Terminated - Clinical trials for Parkinson's Disease (PD)

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

REDWOOD
Start date: February 22, 2019
Phase: Phase 3
Study type: Interventional

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure

NCT ID: NCT03822117 Terminated - Clinical trials for Solid Tumor Malignancy

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Start date: October 17, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.

NCT ID: NCT03820648 Terminated - Clinical trials for Surgical Site Infection

Wound Protector Dual-ring Alexis® in Pancreaticoduodenectomy

PALEXIS
Start date: September 7, 2017
Phase: N/A
Study type: Interventional

Surgical site infection (SSI) is a leading cause of preventable morbidity and mortality in North America and worldwide. This condition has consistently been reported to account for up to 25% of all healthcare-associated infections. In a cost analysis, SSIs post-pancreaticoduodenectomy (PD) dramatically increases the treatment costs. More importantly, postoperative wound infections delay postoperative adjuvant chemotherapy, which is indicated in the majority of patients undergoing PD for pancreatic cancer. Protective covers or 'wound protectors' are hypothesized to be an improvement over adhesive membrane barriers as they are believed to reduce intraoperative contamination while concomitantly preserving the temperature and humidity of the surgical wound. The aim of this study is to assess if the use of wound protector can reduce the wound infection rate in patients undergoing to PD.

NCT ID: NCT03820258 Terminated - Clinical trials for Hepatitis C Virus Infection

Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection

Start date: January 28, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the steady-state pharmacokinetics (PK) and confirm the age-appropriate dose of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) in pediatric participants with chronic hepatitis C virus (HCV) infection.

NCT ID: NCT03819660 Terminated - Clinical trials for Spinal Muscular Atrophy Type 3

Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3

SMA3
Start date: March 7, 2019
Phase: Phase 2
Study type: Interventional

A long term safety study of amifampridine phosphate in patients with spinal muscular atrophy (SMA) Type 3.